Journal
VACCINE
Volume 35, Issue 48, Pages 6591-6593Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2017.09.053
Keywords
Vaccines; Antimicrobial resistance; Antibiotics; Valuation
Categories
Funding
- Bill and Melinda Gates Foundation [OPP1168067]
- Bill and Melinda Gates Foundation [OPP1168067] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Interest in addressing antimicrobial resistance (AMR) has grown recently but little effort has been made to consider how existing and new vaccines could impact on AMR. A 2017 Chatham House meeting considered the role of vaccines and how to demonstrate their value through their impact on AMR. Ways existing vaccines have reduced antibiotic prescribing and the prevalence of some resistant organisms were reviewed. Other new vaccines could have a similar impact. In gonorrhoea, where complete resistance has developed, vaccine may be the best option. Valuing the impact of vaccines on AMR was challenging: there were difficult methodological issues and a lack of data for modelling. A participant poll suggested priorities for accelerated vaccine development were tuberculosis, typhoid, influenza, RSV and gonorrhoea. More evidence is needed to convince policymakers but that vaccine development projects should be considered by funders on the same basis as those for new antibiotics or diagnostics. (C) 2017 The Authors. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available